<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428974</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-201PS</org_study_id>
    <nct_id>NCT00428974</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CF101 to Treat Psoriasis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that CF101, which is under development to treat other&#xD;
      immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of&#xD;
      chronic plaque psoriasis. Patients with psoriasis who qualify for the study will be treated&#xD;
      every 12 hours (q12h) with CF101 capsules, or placebo capsules, for 12 weeks. The safety of&#xD;
      treatment will be carefully assessed through clinical and laboratory monitoring. The effect&#xD;
      of treatment on psoriasis will be evaluated through standard techniques of examination and&#xD;
      measurement of the severity of skin involvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, randomized, double-blind, dose-ranging, placebo-controlled,&#xD;
      study in adult males and females, ages 18 to 70 years, inclusive, with a diagnosis of&#xD;
      moderate-to-severe chronic plaque psoriasis. At the Screening Visit, patients who provide&#xD;
      written informed consent will have screening procedures performed, including a complete&#xD;
      medical history, medication history, physical examination, including height, weight, blood&#xD;
      pressure, pulse rate and temperature, and clinical laboratory tests.&#xD;
&#xD;
      Eligible patients will be those who have not received systemic retinoids, corticosteroids, or&#xD;
      immunosuppressants (e.g., methotrexate, cyclosporine) within 6 weeks prior to initiation of&#xD;
      study; or high potency topical corticosteroids (Class I-III), keratolytics, or coal tar&#xD;
      (other than on the scalp, palms, groin, and/or soles); and UV or Dead Sea therapy within 4&#xD;
      weeks prior to initiation of study treatment. Eligible patients will be sequentially assigned&#xD;
      to 1 of 3 dosing cohorts:&#xD;
&#xD;
      Cohort 1: CF101 1 mg (15 patients) or Placebo (5 patients); Cohort 2: CF101 2 mg (15&#xD;
      patients) or Placebo (5 patients); Cohort 3: CF101 4 mg (15 patients) or Placebo (5&#xD;
      patients).&#xD;
&#xD;
      Medication will be taken orally q12h for 12 weeks. Disease activity will be assessed using&#xD;
      the Psoriasis Area and Severity Index (PASI) and the Physician Global Assessment (PGA).&#xD;
      Patients will return for assessments at Weeks 2, 4, 8, 12 and 14.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score</measure>
    <time_frame>12 weeks minus baseline</time_frame>
    <description>PASI scale is sum of redness, thickness, and scale scores, ranging from 0 (no disease) to 72 (most severe possible score); lower scores, i..e., negative change from baseline, indicate improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Who Achieve a Score of &quot;Almost Clear&quot; or &quot;Clear&quot; by Physician's Global Assessment (PGA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>PGA is a scale from 0 (clear, no disease) to 5 (most severe score); patients who improve to 0 (clear) or 1 (minimal disease) are tabulated in this outcome</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>CF101 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CF101 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CF101 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101 1mg</intervention_name>
    <description>CF101 1 mg q12 hours for 12 weeks</description>
    <arm_group_label>CF101 1 mg</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101 2mg</intervention_name>
    <description>CF101 2 mg q12 hours for 12 weeks</description>
    <arm_group_label>CF101 2mg</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101 4mg</intervention_name>
    <description>CF101 4 mg q12 hours for 12 weeks</description>
    <arm_group_label>CF101 4mg</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets q12 hours for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 18 to 70 years of age, inclusive;&#xD;
&#xD;
          -  Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area&#xD;
             involvement ≥10%, as judged by the Investigator;&#xD;
&#xD;
          -  Duration of psoriasis of at least 6 months;&#xD;
&#xD;
          -  PASI score ≥10;&#xD;
&#xD;
          -  Body weight ≤100 kg;&#xD;
&#xD;
          -  Candidate for systemic treatment or phototherapy for psoriasis;&#xD;
&#xD;
          -  ECG is normal or shows abnormalities which, in the judgment of the Investigator, are&#xD;
             not clinically significant;&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative serum pregnancy test at&#xD;
             screening;&#xD;
&#xD;
          -  Females of child-bearing potential must be willing to use 2 methods of contraception&#xD;
             deemed adequate by the Investigator (for example oral contraceptive pills plus a&#xD;
             barrier method) to be eligible for, and continue participation in, the study;&#xD;
&#xD;
          -  Ability to complete the study in compliance with the protocol; and&#xD;
&#xD;
          -  Ability to understand and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis;&#xD;
&#xD;
          -  Treatment with systemic retinoids, corticosteroids, or immunosuppressants (e.g.,&#xD;
             methotrexate, cyclosporine) within 6 weeks of the Baseline visit;&#xD;
&#xD;
          -  Treatment with high potency topical corticosteroids (Class I-III), keratolytics, or&#xD;
             coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the&#xD;
             Baseline visit;&#xD;
&#xD;
          -  Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated&#xD;
             need for either of these therapies during the study period;&#xD;
&#xD;
          -  Treatment with a biological agent (including etanercept, adalimumab, efalizumab,&#xD;
             infliximab, or alefacept) within a period of time equal to 5 times its circulating&#xD;
             half-life, or 30 days, whichever is longer, prior to the Baseline visit;&#xD;
&#xD;
          -  History of poor clinical response to methotrexate after an adequate regimen and&#xD;
             duration of treatment;&#xD;
&#xD;
          -  Treatment with systemic nonsteroidal anti-inflammatory drugs, beta-blockers, lithium,&#xD;
             hydroxychloroquine, chloroquine, or systemic terbinafine within 2 weeks of the&#xD;
             Baseline visit, or anticipated need for such drugs during the study period;&#xD;
&#xD;
          -  Presence or history of uncontrolled asthma;&#xD;
&#xD;
          -  Presence or history of uncontrolled arterial hypertension or symptomatic hypotension;&#xD;
&#xD;
          -  Significant cardiac arrhythmia or conduction block, congestive heart failure (New York&#xD;
             Heart Association Class 3-4), or any other evidence of clinically significant heart&#xD;
             disease or clinically significant findings on screening electrocardiogram;&#xD;
&#xD;
          -  Hemoglobin level &lt;9.0 gm/L;&#xD;
&#xD;
          -  Platelet count &lt;125,000/mm^3;&#xD;
&#xD;
          -  White blood cell count &lt;3500/mm^3;&#xD;
&#xD;
          -  Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal;&#xD;
&#xD;
          -  Liver aminotransferase levels greater than 2 times the laboratory's upper limit of&#xD;
             normal;&#xD;
&#xD;
          -  Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the&#xD;
             Investigator;&#xD;
&#xD;
          -  History of malignancy within the past 5 years (excluding basal cell carcinoma of the&#xD;
             skin and ≤3 cutaneous squamous cell carcinomas, all of which have been completely&#xD;
             excised);&#xD;
&#xD;
          -  Significant acute or chronic medical or psychiatric illness that, in the judgment of&#xD;
             the Investigator, could compromise patient safety, limit the patient's ability to&#xD;
             complete the study, and/or compromise the objectives of the study;&#xD;
&#xD;
          -  Participation in another investigational drug or vaccine trial concurrently or within&#xD;
             30 days; or within 5 half lives of a biological investigational product, whichever is&#xD;
             longer;&#xD;
&#xD;
          -  Other conditions which would confound the study evaluations or endanger the safety of&#xD;
             the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael David, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 2012 Mar;26(3):361-7. doi: 10.1111/j.1468-3083.2011.04078.x. Epub 2011 Apr 20.</citation>
    <PMID>21504485</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2007</study_first_posted>
  <results_first_submitted>June 20, 2011</results_first_submitted>
  <results_first_submitted_qc>August 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2011</results_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CF101 1 mg Twice Daily (BID)</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>CF101 2 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>CF101 4 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">one patient was randomized but never received study treatment</participants>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF101 1 mg Twice Daily (BID)</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>CF101 2 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>CF101 4 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="12.0"/>
                    <measurement group_id="B2" value="48.4" spread="10.2"/>
                    <measurement group_id="B3" value="45.3" spread="12.1"/>
                    <measurement group_id="B4" value="51.2" spread="10.4"/>
                    <measurement group_id="B5" value="49.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score</title>
        <description>PASI scale is sum of redness, thickness, and scale scores, ranging from 0 (no disease) to 72 (most severe possible score); lower scores, i..e., negative change from baseline, indicate improvement</description>
        <time_frame>12 weeks minus baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CF101 1 mg Twice Daily (BID)</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CF101 2 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>CF101 4 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score</title>
          <description>PASI scale is sum of redness, thickness, and scale scores, ranging from 0 (no disease) to 72 (most severe possible score); lower scores, i..e., negative change from baseline, indicate improvement</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="8.9"/>
                    <measurement group_id="O2" value="-8.8" spread="7.0"/>
                    <measurement group_id="O3" value="-4.1" spread="7.8"/>
                    <measurement group_id="O4" value="-2.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 weeks, 2mg CF101 vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Who Achieve a Score of &quot;Almost Clear&quot; or &quot;Clear&quot; by Physician's Global Assessment (PGA)</title>
        <description>PGA is a scale from 0 (clear, no disease) to 5 (most severe score); patients who improve to 0 (clear) or 1 (minimal disease) are tabulated in this outcome</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CF101 1 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CF101 2 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>CF101 4 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Who Achieve a Score of &quot;Almost Clear&quot; or &quot;Clear&quot; by Physician's Global Assessment (PGA)</title>
          <description>PGA is a scale from 0 (clear, no disease) to 5 (most severe score); patients who improve to 0 (clear) or 1 (minimal disease) are tabulated in this outcome</description>
          <units>Number of treated patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <desc>All adverse events were collected and verbatim terms were coded via MedDRA dictionary</desc>
      <group_list>
        <group group_id="E1">
          <title>CF101 1 mg Twice Daily (BID)</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>CF101 2 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>CF101 4 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine oxalate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pnina Fishman, PhD</name_or_title>
      <organization>Can-Fite BioPharma Ltd</organization>
      <phone>011972 3 924 1114</phone>
      <email>pnina@canfite.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

